医学
外科
置信区间
放射治疗
脑转移
立体定向放射治疗
随机对照试验
不利影响
放射外科
外科切除术
比例危险模型
立体定向放射治疗
人口
放射科
切除术
临床试验
立体定向手术
临床研究阶段
转移
回顾性队列研究
入射(几何)
中枢神经系统疾病
总体生存率
生存分析
作者
Jeffrey S. Weinberg,Brandon S. Imber,Vincent A. DiNapoli,Nelson S. Moss,Kimberly Bojanowski Hoang,Fen Wang,I. Mohiuddin,Akshitkumar M. Mistry,Michael A. Garcia,Hussein A. Tawbi,Nitesh V. Patel,H PHAM,Robert Ryan,John E. Wanebo,Kris Smith,Clark C. Chen,Alexandra Paul,Lindsey Sloan,Matthew J. Shepard,Ken Tatebe
摘要
PURPOSE: Post-operative stereotactic radiation (SRT) is the standard-of-care for resected brain metastases. Implantation of cesium-131 collagen tiles (tile-based radiation therapy, TBRT) initiates focal radiation immediately after resection, potentially offering therapeutic and logistical advantages. ROADS: a randomized, open-label, non-inferiority, phase 3 trial (NCT04365374) compared the safety and efficacy of resection with TBRT (R+TBRT) to resection with SRT (R+SRT) for patients with a newly diagnosed brain metastasis indicated for surgical resection. PATIENTS AND METHODS: Across 32 United States centers, patients were pre-operatively randomized 1:1 to resection R+TBRT or R+SRT. Any non-resected brain metastases received SRT post-operatively. Co-primary outcomes were time-to-surgical bed recurrence (SBR) and surgical bed recurrence-free survival (SB-RFS). Outcomes were analyzed using Cox proportional hazards models with stratification factors as covariates. Multiplicity was controlled by hierarchical testing. Analyses used the pre-specified modified intent-to-treat (mITT) population (patients who underwent surgery, had pathologic confirmation of brain metastasis, and had follow-up information). RESULTS: From April 2021 through August 2025, 230 patients were randomized (115 per arm); 204 of whom (103 R+TBRT, 101 R+SRT) comprised the mITT population. Median follow-up was 12.9 months. Median time-to-SBR was not reached (R+TBRT) versus 17.4 months (R+SRT) (hazard ratio [HR]: 0.06; 95% confidence interval [CI]: 0.01-0.46; p=0.0070). SB-RFS was improved with R+TBRT, with a median of not reached versus 10.9 months (R+SRT) (HR: 0.48; 95% CI: 0.30-0.76; p=0.0021). Overall adverse events did not appear to differ: 83 patients (79.0%, 95% CI: 70.0-86.4) (R+TBRT) versus 67 patients (80.7%, 95% CI:70.6-88.6) (R+SRT). CONCLUSION: For patients with newly diagnosed brain metastases requiring resection, R+TBRT significantly improved SBR and SB-RFS, demonstrating both non-inferiority and superiority.
科研通智能强力驱动
Strongly Powered by AbleSci AI